McConnell Says Won’t Vote To Proceed On Chips Bill At This Stage

– Reuters

– Reuters

Total
0
Shares
Related Posts
Read More

Takeda Announces Late-Breaking Data From Phase 2b Study Of TAK-279, An Investigational, Oral, Once-Daily TYK2 Inhibitor, In Patients With Active Psoriatic Arthritis At American College Of Rheumatology Convergence Annual Meeting

− The Study Met Its Primary Endpoint with 53.3% and 54.2% of Patients Treated With TAK-279 (15 mg and 30 mg Respectively) Achieving At Least an ACR 20 Response Compared to 29.2% in the Placebo Group at Week 12 (p =

TAK